Log in

Relevant bibliographies by topics / Metastatic progression / Journal articles

To see the other types of publications on this topic, follow the link: Metastatic progression.

Journal articles on the topic 'Metastatic progression'

Author: Grafiati

Published: 9 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Metastatic progression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Roda, Niccolo’, Valentina Gambino, and Marco Giorgio. "Metabolic Constrains Rule Metastasis Progression." Cells 9, no. 9 (2020): 2081. http://dx.doi.org/10.3390/cells9092081.

Full text

Abstract:

Metastasis formation accounts for the majority of tumor-associated deaths and consists of different steps, each of them being characterized by a distinctive adaptive phenotype of the cancer cells. Metabolic reprogramming represents one of the main adaptive phenotypes exploited by cancer cells during all the main steps of tumor and metastatic progression. In particular, the metabolism of cancer cells evolves profoundly through all the main phases of metastasis formation, namely the metastatic dissemination, the metastatic colonization of distant organs, the metastatic dormancy, and ultimately t

APA, Harvard, Vancouver, ISO, and other styles

2

Morgans, Alicia K., Christopher Sweeney, Christopher J. D. Wallis, et al. "Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS." Journal of Clinical Oncology 40, no. 16_suppl (2022): 5044. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5044.

Full text

Abstract:

5044 Background: Darolutamide (DARO), a highly potent and structurally distinct androgen receptor inhibitor, prolonged metastasis-free survival by nearly 2 years and reduced the risk of death by 31% vs placebo (PBO) with a favorable tolerability profile in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in ARAMIS. We present post-hoc analyses of ARAMIS to evaluate the association between metastatic progression with prostate-specific antigen (PSA) and clinical progression and to describe the distribution of metastatic progression between groups. Methods: Pts with

APA, Harvard, Vancouver, ISO, and other styles

3

Morgans, Alicia K., Christopher Sweeney, Christopher J. D. Wallis, et al. "Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS." Journal of Clinical Oncology 40, no. 16_suppl (2022): 5044. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5044.

Full text

Abstract:

5044 Background: Darolutamide (DARO), a highly potent and structurally distinct androgen receptor inhibitor, prolonged metastasis-free survival by nearly 2 years and reduced the risk of death by 31% vs placebo (PBO) with a favorable tolerability profile in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in ARAMIS. We present post-hoc analyses of ARAMIS to evaluate the association between metastatic progression with prostate-specific antigen (PSA) and clinical progression and to describe the distribution of metastatic progression between groups. Methods: Pts with

APA, Harvard, Vancouver, ISO, and other styles

4

Park, Sun H., Shunsuke Tsuzuki, Kelly F. Contino, et al. "Crosstalk between bone metastatic cancer cells and sensory nerves in bone metastatic progression." Life Science Alliance 7, no. 12 (2024): e202302041. http://dx.doi.org/10.26508/lsa.202302041.

Full text

Abstract:

Although the role of peripheral nerves in cancer progression has been appreciated, little is known regarding cancer/sensory nerve crosstalk and its contribution to bone metastasis and associated pain. In this study, we revealed that the cancer/sensory nerve crosstalk plays a crucial role in bone metastatic progression. We found that (i) periosteal sensory nerves expressing calcitonin gene–related peptide (CGRP) are enriched in mice with bone metastasis; (ii) cancer patients with bone metastasis have elevated CGRP serum levels; (iii) bone metastatic patient tumor samples express elevated calcit

APA, Harvard, Vancouver, ISO, and other styles

5

Seely, Kevin D., Amanda D. Morgan, Lauren D. Hagenstein, Garrett M. Florey, and James M. Small. "Bacterial Involvement in Progression and Metastasis of Colorectal Neoplasia." Cancers 14, no. 4 (2022): 1019. http://dx.doi.org/10.3390/cancers14041019.

Full text

Abstract:

While the gut microbiome is composed of numerous bacteria, specific bacteria within the gut may play a significant role in carcinogenesis, progression, and metastasis of colorectal carcinoma (CRC). Certain microbial species are known to be associated with specific cancers; however, the interrelationship between bacteria and metastasis is still enigmatic. Mounting evidence suggests that bacteria participate in cancer organotropism during solid tumor metastasis. A critical review of the literature was conducted to better characterize what is known about bacteria populating a distant site and whe

APA, Harvard, Vancouver, ISO, and other styles

6

Albini, Adriana, and József Tímár. "Genomics of metastatic progression." Clinical & Experimental Metastasis 27, no. 6 (2010): 453. http://dx.doi.org/10.1007/s10585-010-9348-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Visentin, Sarah, Mirela Sedić, Sandra Kraljević Pavelić, and Krešimir Pavelić. "Targeting Tumour Metastasis: The Emerging Role of Nanotechnology." Current Medicinal Chemistry 27, no. 8 (2020): 1367–81. http://dx.doi.org/10.2174/0929867326666181220095343.

Full text

Abstract:

The metastatic process has still not been completely elucidated, probably due to insufficient knowledge of the underlying mechanisms. Here, we provide an overview of the current findings that shed light on specific molecular alterations associated with metastasis and present novel concepts in the treatment of the metastatic process. In particular, we discuss novel pharmacological approaches in the clinical setting that target metastatic progression. New insights into the process of metastasis allow optimisation and design of new treatment strategies, especially in view of the fact that metasta

APA, Harvard, Vancouver, ISO, and other styles

8

Rupp, Kevin, Andreas Lösch, Yanren Linda Hu, et al. "Modeling metastatic progression from cross-sectional cancer genomics data." Bioinformatics 40, Supplement_1 (2024): i140—i150. http://dx.doi.org/10.1093/bioinformatics/btae250.

Full text

Abstract:

Abstract Motivation Metastasis formation is a hallmark of cancer lethality. Yet, metastases are generally unobservable during their early stages of dissemination and spread to distant organs. Genomic datasets of matched primary tumors and metastases may offer insights into the underpinnings and the dynamics of metastasis formation. Results We present metMHN, a cancer progression model designed to deduce the joint progression of primary tumors and metastases using cross-sectional cancer genomics data. The model elucidates the statistical dependencies among genomic events, the formation of metas

APA, Harvard, Vancouver, ISO, and other styles

9

Mitra, Sumegha, Kartikeya Tiwari, Ram Podicheti, et al. "Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression." Cancers 11, no. 10 (2019): 1513. http://dx.doi.org/10.3390/cancers11101513.

Full text

Abstract:

Background: Ovarian cancer is the most lethal gynecologic malignancy. There is a lack of comprehensive investigation of disease initiation and progression, including gene expression changes during early metastatic colonization. Methods: RNA-sequencing (RNA-seq) was done with matched primary tumors and fallopian tubes (n = 8 pairs) as well as matched metastatic and primary tumors (n = 11 pairs) from ovarian cancer patients. Since these are end point analyses, it was combined with RNA-seq using high-grade serous ovarian cancer cells seeded on an organotypic three-dimensional (3D) culture model o

APA, Harvard, Vancouver, ISO, and other styles

10

Eckhardt, Bedrich L., Belinda S. Parker, Ryan K. van Laar, et al. "Genomic Analysis of a Spontaneous Model of Breast Cancer Metastasis to Bone Reveals a Role for the Extracellular Matrix." Molecular Cancer Research 3, no. 1 (2005): 1–13. http://dx.doi.org/10.1158/1541-7786.1.3.1.

Full text

Abstract:

Abstract A clinically relevant model of spontaneous breast cancer metastasis to multiple sites, including bone, was characterized and used to identify genes involved in metastatic progression. The metastatic potential of several genetically related tumor lines was assayed using a novel real-time quantitative RT-PCR assay of tumor burden. Based on this assay, the tumor lines were categorized as nonmetastatic (67NR), weakly metastatic to lymph node (168FARN) or lung (66cl4), or highly metastatic to lymph node, lung, and bone (4T1.2 and 4T1.13). In vitro assays that mimic stages of metastasis sho

APA, Harvard, Vancouver, ISO, and other styles

11

Shiraishi, Kenshiro, Keiichiro Tada, Jiro Kawamori, Atsushi Fukuuchi, and Tsunehiro Nishi. "Disease progression of metastatic breast cancer by first relapse site after definitive radiotherapy." Journal of Clinical Oncology 33, no. 28_suppl (2015): 36. http://dx.doi.org/10.1200/jco.2015.33.28_suppl.36.

Full text

Abstract:

36 Background: Bone metastasis as initial distant relapse is commonly considered to have better prognosis than other sites in metastatic breast cancer. To elucidate true clinical course of metastatic disease, it is essential that we prospectively manage patients since primary setting. Methods: Overall, 3,417 patients with breast cancer treated with mastectomy (n = 379, 11.1%) or breast-conserving surgery (n = 3,029, 88.6%) followed by definitive radiotherapy at two institutions in Center of Tokyo between 1980 and 2014 were included in the study. Information on all patients was prospectively co

APA, Harvard, Vancouver, ISO, and other styles

12

Hu, Dandan, Gong Chen, Yaojun Zhang, and Minshan Chen. "Next generation sequencing reveals the phylogenetic relationship of multi-organ metastatic colon cancer and molecular determinants of metastasis." Journal of Clinical Oncology 38, no. 15_suppl (2020): e13502-e13502. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e13502.

Full text

Abstract:

e13502 Background: The clinical manifestation of metastatic colorectal cancer (mCRC) varies from patient to patient, with the underlying genetic alterations and expression profiles deceptive. We aim to investigate the phylogenetic relationships of the multi-organ mCRC and the possible biomarkers of disease progression. Methods: Whole Extron Sequencing (WES) was performed in CRC and their matched multi-organ metastases from three patients with different clinical manifestations. Sciclone calculation between individual lesions illustrated the evolutionary origins of each metastatic sites. Genomic

APA, Harvard, Vancouver, ISO, and other styles

13

Chen, Jocelyn F., and Qin Yan. "The roles of epigenetics in cancer progression and metastasis." Biochemical Journal 478, no. 17 (2021): 3373–93. http://dx.doi.org/10.1042/bcj20210084.

Full text

Abstract:

Cancer metastasis remains a major clinical challenge for cancer treatment. It is therefore crucial to understand how cancer cells establish and maintain their metastatic traits. However, metastasis-specific genetic mutations have not been identified in most exome or genome sequencing studies. Emerging evidence suggests that key steps of metastasis are controlled by reversible epigenetic mechanisms, which can be targeted to prevent and treat the metastatic disease. A variety of epigenetic mechanisms were identified to regulate metastasis, including the well-studied DNA methylation and histone m

APA, Harvard, Vancouver, ISO, and other styles

14

Gerbec, Zachary J., Antonio Serapio-Palacios, Sarah E. Woodword, Jorge Pena Diaz, Brett Finlay, and Shoukat Dedhar. "Abstract A047: Tumor-derived bacteria drive breast cancer metastasis." Cancer Research 83, no. 2_Supplement_2 (2023): A047. http://dx.doi.org/10.1158/1538-7445.metastasis22-a047.

Full text

Abstract:

Abstract Metastasis is a major barrier to long-term survival and therapeutic options for aggressive, metastatic forms of breast cancer remain limited. Studies using patient samples have identified tumor-resident bacteria that preferentially associate with specific breast cancer types including highly aggressive TNBC. However, it is not yet understood how intratumoral bacteria directly contributes to disease progression and metastatic propensity independent of other prognostic factors. It is therefore the goal of the Dedhar and Finlay labs to identify how specific bacteria within metastatic bre

APA, Harvard, Vancouver, ISO, and other styles

15

Entwistle, Susannah, Hannah K. Jackson, Ian Kerr, Beth Coyle, and Alistair Hume. "MEDB-64. Are Rab GTPases metastatic drivers in metastatic medulloblastoma?" Neuro-Oncology 24, Supplement_1 (2022): i121. http://dx.doi.org/10.1093/neuonc/noac079.438.

Full text

Abstract:

Abstract Medulloblastoma is the most common malignant paediatric brain cancer with poorer prognosis related to the onset of metastasis. It has four molecular subgroups; Wingless (WNT), Sonic Hedgehog (SHH), group 3 and group 4, of which group 3 is the most likely to be metastatic and is therefore associated with the poorest prognosis. Exosomes are small membrane-bound extracellular vesicles of endosomal origin which contain a variety of cargo including RNA and proteins. Increased exosome release is connected with disease progression and metastasis in multiple cancers. Rabs are a family of smal

APA, Harvard, Vancouver, ISO, and other styles

16

Stephenson, Andrew J., Michael W. Kattan, James A. Eastham, et al. "Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition." Journal of Clinical Oncology 24, no. 24 (2006): 3973–78. http://dx.doi.org/10.1200/jco.2005.04.0756.

Full text

Abstract:

Purpose Prostate-specific antigen (PSA) defined biochemical recurrence (BCR) of prostate cancer is widely used for reporting the outcome of radical prostatectomy (RP). A standardized BCR definition is lacking, and overall progression-free probability and risk of subsequent metastatic disease progression may vary greatly depending on the PSA criterion used. Ten definitions of BCR were evaluated to identify the one that best explains metastatic progression. Methods Of 3,125 patients who underwent RP at our institution since 1985, 75 developed distant metastasis during a median follow-up of 49 mo

APA, Harvard, Vancouver, ISO, and other styles

17

Dilmac, Sayra, Nilay Kuscu, Ayse Caner, et al. "SIRT1/FOXO Signaling Pathway in Breast Cancer Progression and Metastasis." International Journal of Molecular Sciences 23, no. 18 (2022): 10227. http://dx.doi.org/10.3390/ijms231810227.

Full text

Abstract:

Breast cancer is the second most common cancer in women. The roles of the SIRT and FoxO proteins in tumor progression are known, but their roles in metastasis have not yet been clearly elucidated. In our study, we investigated the roles of SIRT and FoxO proteins their downstream pathways, proteins p21 and p53, in tumor progression and metastasis. We evaluated these proteins in vitro using metastatic 4TLM and 67NR cell lines, as well as their expression levels in tumor-bearing mice. In addition, the regulatory role of SIRT and FoxO proteins in different transduction cascades was examined by IPA

APA, Harvard, Vancouver, ISO, and other styles

18

Hovens, Christopher, Matthew Hong, Geoff Macintyre, et al. "Tracking clonal diversity in metastatic prostate cancer progression." Journal of Clinical Oncology 33, no. 7_suppl (2015): 193. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.193.

Full text

Abstract:

193 Background: Genomic heterogeneity has been observed in a number of tumor types including prostate cancer. However, how subclonal tumor diversity changes during metastasis and progression to lethality remains unexplored. Large scale genomic analyses have reported the most prevalent somatic aberrations associated with the dominant clone of the tumor without permitting an analysis of subclonal complexity or how this complexity impinges on metastatic potential or resistance to treatment. Methods: To understand and track the evolution of lethal prostate cancer from initial therapy to end stage

APA, Harvard, Vancouver, ISO, and other styles

19

Karlow, Jennifer A., Siddhartha Devarakonda, Xiaoyun Xing, et al. "Developmental Pathways Are Epigenetically Reprogrammed during Lung Cancer Brain Metastasis." Cancer Research 82, no. 15 (2022): 2692–703. http://dx.doi.org/10.1158/0008-5472.can-21-4160.

Full text

Abstract:

Abstract Non–small cell lung cancer (NSCLC) is one of the most commonly diagnosed and deadliest cancers worldwide, with roughly half of all patients initially presenting with both primary and metastatic disease. While the major events in the metastatic cascade have been identified, a mechanistic understanding of how NSCLC routinely and successfully colonizes the brain is largely unknown. Recent studies have begun demonstrating the role of epigenetic misregulation during tumorigenesis and metastasis, including widespread changes in DNA methylation and histone modifications. To better understand

APA, Harvard, Vancouver, ISO, and other styles

20

Green, Foad H., Matthew J. Rioth, and Joshua Loving. "Sequential learning for pan-tumor detection of metastatic disease progression." Journal of Clinical Oncology 41, no. 16_suppl (2023): e13591-e13591. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13591.

Full text

Abstract:

e13591 Background: Detection of progression of patients with early stage cancer is a challenge for real world data from electronic health records (EHR). Temporal patterns common to patients’ data can detect patients with metastatic progression. A deep learning approach on longitudinal patient records of cancer lab testing, visit diagnosis codes, and cancer treatments was used to identify metastatic status. Methods: ICD-10-CM diagnosis codes, clinical lab values specific to cancer testing, and antineoplastic treatments were evaluated from longitudinal data of 128,614 patients who did not progre

APA, Harvard, Vancouver, ISO, and other styles

21

Oliveira, Renata Ramalho, Douglas V. Faget, Xianmin Luo, Jiayu Ye, Joseph B. Monahan, and Sheila A. Stewart. "Abstract 244: Limiting metastatic breast cancer progression by targeting MK2 stromal signaling." Cancer Research 82, no. 12_Supplement (2022): 244. http://dx.doi.org/10.1158/1538-7445.am2022-244.

Full text

Abstract:

Abstract Breast cancer is now the most common cancer among women in the US and metastasis to distant organs is the major cause of death in these patients. Among metastatic sites, bone is the most frequent destination of breast cancer metastasis and once the disease is found in the bone, it is often refractory to standard therapy. In addition, bone metastasis is associated with significant skeletal related events that greatly impact quality of life. Thus, there is a significant need to develop novel therapies that extend survival and improve quality of life. Previously we found that MK2 inhibit

APA, Harvard, Vancouver, ISO, and other styles

22

Zarrella, Mark, Joon Kyoo Lee MD, and Sang-Chul Lim. "R412 – Role of KITENIN in Progression and Metastasis of SCC." Otolaryngology–Head and Neck Surgery 139, no. 2_suppl (2008): P181. http://dx.doi.org/10.1016/j.otohns.2008.05.566.

Full text

Abstract:

Problem The expression of KAI1 (a metastatic suppressor gene) in cancer cells results in reduced cell motility and invasiveness. A cDNA clone of VANGL1, a member of the tetraspanin protein family that specifically interacts with the COOH-terminal cytoplasm domain of KAI1, was isolated and renamed KITENIN (KAI1 COOH-terminal interacting tetraspanin). The purpose of this study was to investigate the role of KITENIN on the progression and metastasis of transfected squamous cell carcinoma using in vivo and in vitro experiments. Methods Locally advanced squamous cell carcinoma tissues from five pat

APA, Harvard, Vancouver, ISO, and other styles

23

Nestler, Tim, Priya Dalvi, Friederike Haidl, et al. "Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours." British Journal of Cancer 126, no. 6 (2022): 937–47. http://dx.doi.org/10.1038/s41416-021-01621-5.

Full text

Abstract:

Abstract Background Testicular germ cell tumours (TGCTs) have a high metastasis rate. However, the mechanisms related to their invasion, progression and metastasis are unclear. Therefore, we investigated gene expression changes that might be linked to metastasis in seminomatous testicular germ cell tumour (STGCT) patients. Methods Defined areas [invasive tumour front (TF) and tumour centre (TC)] of non-metastatic (with surveillance and recurrence-free follow-up >2 years) and metastatic STGCTs were collected separately using laser capture microdissection. The expression of 760 genes related

APA, Harvard, Vancouver, ISO, and other styles

24

Audouin, Marie, Géraldine Cancel Tassin, Cécile Gaffory, et al. "Association of Rs1139971, a KAI1 polymorphism, with bone metastasis progression in prostate cancer and ganglionnary metastasis." Journal of Clinical Oncology 31, no. 15_suppl (2013): e16089-e16089. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e16089.

Full text

Abstract:

e16089 Background: Metastatic prostate cancer, with bones as principal location, is responsible for most of the death from this malignancy. If the molecular mecanisms of the metastasis progression are not completely solved, many involved pathways have been clarified. Association studies have proven that genetic factors could affect the risk of prostate cancer or its agressiveness. Likewise, some polymorphisms from genes involved in metastatic pathways could have a meaningfull function in the individual genetic susceptibility to metastatic prostate cancer. The KAI1 gene is known to be implicate

APA, Harvard, Vancouver, ISO, and other styles

25

McDonald, Erica, Sierra Cheng, Vanessa S. Arciero, et al. "Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy." Journal of Clinical Oncology 35, no. 6_suppl (2017): e587-e587. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.e587.

Full text

Abstract:

e587 Background: SABR is increasingly used for the treatment of men with oligometastatic prostate cancer, including patients (pts) presenting with oligoprogression. The latter is a clinical situation where a limited number of metastatic tumor sites progress (usually defined as ≤ 3-5), while all other metastases are controlled by a given systemic therapy. The frequency of oligoprogression potentially amenable to SABR is unknown. Methods: Thus, in a retrospective chart analysis we studied the progression pattern of 35 men with chemotherapy-naïve mCRPC undergoing AA therapy, and of 20 men undergo

APA, Harvard, Vancouver, ISO, and other styles

26

McDonald, Erica, Sierra Cheng, Vanessa Sarah Arciero, et al. "Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy." Journal of Clinical Oncology 35, no. 15_suppl (2017): e16509-e16509. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16509.

Full text

Abstract:

e16509 Background: SABR is increasingly used for treating men with oligometastatic prostate cancer, a state between loco-regional and widespread metastatic disease that exists de novo, presents as oligorecurrence, is treatment-induced, or occurs as oligoprogression. The latter is a clinical situation where a limited number of metastatic tumor sites progress (usually defined as ≤3-5), while all other metastases are controlled by a given systemic therapy. The frequency of oligoprogression amenable to SABR is unknown. Methods: Thus, in a retrospective chart analysis we studied the progression pat

APA, Harvard, Vancouver, ISO, and other styles

27

Suh, Jeong Yoon, Se Jung Maeng, Mirinae Kim, Su Jeong Kang, Young Wook Choi, and In Ho Chang. "Current Trends in Liquid Biopsy Technology for Early Diagnosis of Metastatic Renal Cell Carcinoma." Korean Journal of Urological Oncology 20, no. 4 (2022): 223–34. http://dx.doi.org/10.22465/kjuo.2022.20.4.223.

Full text

Abstract:

Clear cell renal cell carcinoma (ccRCC) is a disease with a wide variety of clinical progressions such as the rate of disease progression or the degree of metastasis. About 30% of ccRCC patients suffer from metastatic diseases, and about 30% develop metastasis after diagnosis. In the case of metastatic RCC, early prediction of the disease is important because of the poor prognosis, but ccRCC-specific molecular markers for clinical use are not available yet. As an alternative, liquid biopsy, which can find molecules released from tumor tissues in circulating blood and obtain information on meta

APA, Harvard, Vancouver, ISO, and other styles

28

Ajithkumar, Priyadarshana, Sai Shyam Vasantharajan, Sharon Pattison, John L. McCall, Euan J. Rodger, and Aniruddha Chatterjee. "Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis." International Journal of Molecular Sciences 25, no. 2 (2024): 874. http://dx.doi.org/10.3390/ijms25020874.

Full text

Abstract:

Metastatic progression is a complex, multistep process and the leading cause of cancer mortality. There is growing evidence that emphasises the significance of epigenetic modification, specifically DNA methylation and histone modifications, in influencing colorectal (CRC) metastasis. Epigenetic modifications influence the expression of genes involved in various cellular processes, including the pathways associated with metastasis. These modifications could contribute to metastatic progression by enhancing oncogenes and silencing tumour suppressor genes. Moreover, specific epigenetic alteration

APA, Harvard, Vancouver, ISO, and other styles

29

Gründker, Carsten, Matthias Läsche, Johanna Hellinger, and Günter Emons. "Mechanisms of Metastasis and Cell Mobility – The Role of Metabolism." Geburtshilfe und Frauenheilkunde 79, no. 02 (2019): 184–88. http://dx.doi.org/10.1055/a-0805-9113.

Full text

Abstract:

AbstractTumour metastasis is responsible for more than 90% of tumour-associated mortality. About one third of breast cancer patients in the early stage develop metastases. The transformation in tumour development referred to as the “metastatic cascade” or “metastatic cycle” is a complex and multi-stage event. While it is generally recognised that epithelial-mesenchymal transformation (EMT) plays a crucial role in cancer progression and metastasis, the metabolic events in this process have received little attention to date. We would therefore like to provide a brief overview here of the influen

APA, Harvard, Vancouver, ISO, and other styles

30

Bodogai, Monica, Purevdorj Olkhanud, Yrina Rochman, et al. "Thymic stromal lymphopoietin mediates breast cancer progression and metastasis (48.9)." Journal of Immunology 186, no. 1_Supplement (2011): 48.9. http://dx.doi.org/10.4049/jimmunol.186.supp.48.9.

Full text

Abstract:

Abstract Breast cancer escape and metastasis is an active process that requires inflammation and participation of immune cells. We have previously reported that this is a primary tumor-controlled process which activates lungs to produce CCL17 and CCL22 to facilitate lung metastasis together with the recruitment of CCR4+ regulatory T cells (Tregs). To understand the mechanism of this process, we performed expression array analysis in both metastatic and non-metastatic cancer cells and found that metastatic cells produced thymic stromal lymphopoietin (TSLP), an IL-7-like type 1 inflammatory cyto

APA, Harvard, Vancouver, ISO, and other styles

31

Knuutila, Jaakko S., Pilvi Riihilä, Liisa Nissinen, Roosa Kallionpää, Teijo Pellinen, and Veli-Matti Kähäri. "Abstract 2101: Cancer-associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma." Cancer Research 83, no. 7_Supplement (2023): 2101. http://dx.doi.org/10.1158/1538-7445.am2023-2101.

Full text

Abstract:

Abstract Purpose: Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer and the metastatic disease is associated with poor prognosis. At present, no established biomarkers are available for predicting the metastasis risk and prognosis of patients with cSCC. Cancer-associated fibroblasts (CAFs) promote the progression of cancer, but their role in cSCC is largely unknown. Here, we have examined the potential of CAF markers in the assessment of metastasis risk and prognosis of primary cSCC. Experimental Design: We utilized multiplexed fluorescence immunohistochemistry

APA, Harvard, Vancouver, ISO, and other styles

32

Lin, Siyue, Soonbum Park, Alexander Chui, et al. "Abstract 3932: Elucidating mechanisms of metastatic progression in bladder cancer with novel GEMMs and systems biology approaches." Cancer Research 85, no. 8_Supplement_1 (2025): 3932. https://doi.org/10.1158/1538-7445.am2025-3932.

Full text

Abstract:

Abstract Metastasis is the leading cause of bladder cancer deaths. Despite recent advances in treatment, metastatic bladder cancer remains incurable. One of the major challenges in studying metastasis has been the lack of suitable in vivo models that recapitulate the natural evolution of metastatic progression within the native tumor microenvironment. To address this, we have generated genetically-engineered mouse models (GEMMs) of bladder cancer that have highly penetrant metastatic phenotypes. In particular, our new metastatic GEMMs build on our previously established GEMM, in which bladder-

APA, Harvard, Vancouver, ISO, and other styles

33

Müller, Christian, Sabine Franke, Timo Reisländer, Verena Keitel, and Marino Venerito. "Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports." Case Reports in Oncology 17, no. 1 (2024): 753–62. http://dx.doi.org/10.1159/000539665.

Full text

Abstract:

Introduction: Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median progression-free survival (PFS) benefit of 1.3 months compared to placebo in the phase 3 ClarIDHy trial. Case Presentations: We describe 2 consecutive patients with previously treated unresectable and metastatic iCCA harboring an IDH1 R132 mutation who achieved durable clinical responses with ivosidenib 500 mg once daily for >12 months until disease progression. In one case with a mixed response, a single progressive l

APA, Harvard, Vancouver, ISO, and other styles

34

Westlake, Babe, Jeffrey Brown, Jacqueline Hart, Cameron Skiby, Kevin Jones, and John Groundland. "Exploring the Diagnostic Dilemma of Indeterminate Pulmonary Nodules in Patients with Primary Sarcoma of Bone." Sarcoma 2024 (March 5, 2024): 1–13. http://dx.doi.org/10.1155/2024/9926675.

Full text

Abstract:

Introduction. Bone sarcomas are known to have a predilection for pulmonary metastasis. Surveillance protocols are thus focused on periodic chest imaging, typically with CT scan. Pulmonary nodules can be easily identified with this modality, but smaller nodules are not readily biopsied and may not represent metastatic disease. These are called indeterminate. The natural history of indeterminate nodules in a bone sarcoma population and factors associated with progression to true metastatic disease are not clearly defined. Methods. All bone sarcoma patients treated at a single institution from 20

APA, Harvard, Vancouver, ISO, and other styles

35

Bartoszyński, Robert. "On metastatic progression of cancer." Advances in Applied Probability 17, no. 2 (1985): 245–46. http://dx.doi.org/10.2307/1427131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Bartoszyński, Robert. "On metastatic progression of cancer." Advances in Applied Probability 17, no. 02 (1985): 245–46. http://dx.doi.org/10.1017/s0001867800014877.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Rodolfo, Monica, Maria Daniotti, and Viviana Vallacchi. "Genetic progression of metastatic melanoma." Cancer Letters 214, no. 2 (2004): 133–47. http://dx.doi.org/10.1016/j.canlet.2004.06.049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Usmani, B. A. "Genomic Instability and Metastatic Progression." Pathobiology 61, no. 2 (1993): 109–16. http://dx.doi.org/10.1159/000163771.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Tímár, József, and Andrea Ladányi. "Metastatic Progression of Human Melanoma." Cancers 15, no. 4 (2023): 1225. http://dx.doi.org/10.3390/cancers15041225.

Full text

Abstract:

This Topical Collection, comprising 13 papers (10 original articles and 3 reviews), addresses various aspects of the field of melanoma progression: genomic and proteomic approaches, experimental studies, the questions of sentinel lymph node dissection, and metastasis formation of uveal and conjunctival melanomas is also discussed [...]

APA, Harvard, Vancouver, ISO, and other styles

40

Askeland, Eric J., Vincent A. Chehval, Ryan W. Askeland, et al. "Cell cycle progression score to predict metastatic progression of clear cell renal cell carcinoma after resection." Journal of Clinical Oncology 32, no. 4_suppl (2014): 442. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.442.

Full text

Abstract:

442 Background: Clear cell renal cell carcinoma (ccRCC) is primarily treated surgically when organ confined, but requires close follow-up to evaluate for recurrence. Expression levels of cell cycle progression (CCP) genes have prognostic value in certain cancers. We evaluated the prognostic value of the CCP expression in surgically resected ccRCC. Methods: Medical records were retrospectively reviewed. Patients with metastasis or lymph node involvement at surgery were excluded. Cases developed metastasis within 5 years of resection; controls were followed for at least 4.5 years without recurre

APA, Harvard, Vancouver, ISO, and other styles

41

Biswas, Anup K., and Swarnali Acharyya. "Cancer-Associated Cachexia: A Systemic Consequence of Cancer Progression." Annual Review of Cancer Biology 4, no. 1 (2020): 391–411. http://dx.doi.org/10.1146/annurev-cancerbio-030419-033642.

Full text

Abstract:

Cancer is a life-threatening disease that has plagued humans for centuries. The vast majority of cancer-related mortality results from metastasis. Indeed, the invasive growth of metastatic cancer cells in vital organs causes fatal organ dysfunction, but metastasis-related deaths also result from cachexia, a debilitating wasting syndrome characterized by an involuntary loss of skeletal muscle mass and function. In fact, about 80% of metastatic cancer patients suffer from cachexia, which often renders them too weak to tolerate standard doses of anticancer therapies and makes them susceptible to

APA, Harvard, Vancouver, ISO, and other styles

42

Chousakos, Emmanouil, Daniela Zugna, Emi Dika, et al. "Topographical and Chronological Analysis of Thin Cutaneous Melanoma’s Progressions: A Multicentric Study." Cancers 15, no. 15 (2023): 3989. http://dx.doi.org/10.3390/cancers15153989.

Full text

Abstract:

A great portion of cutaneous melanoma’s diagnoses nowadays is attributed to thin tumors with up to 1 mm in Breslow thickness (hereafter thin CMs), which occasionally metastasize. The objective of this study was to identify thin CM’s metastatic patterns from a topographical and chronological standpoint. A total of 204 cases of metastatic thin CMs from five specialized centers were included in the study, and corresponding data were collected (clinical, epidemiological, histopathological information of primary tumor and the number, anatomical site, and time intervals of their progressions). First

APA, Harvard, Vancouver, ISO, and other styles

43

Park, Joo Un, and Jae Wan Jung. "Metastatic ameloblastoma with postoperative accelerated tumor growth treated with carboplatin and paclitaxel: a case report." Kosin Medical Journal 37, no. 1 (2022): 83–88. http://dx.doi.org/10.7180/kmj.21.030.

Full text

Abstract:

Ameloblastoma is a histologically benign odontogenic epithelial tumor that rarely metastasizes. However, metastasis to the lungs can occur, usually years after the development of the primary tumor. Here, we present the case of a 63-year-old woman with metastatic ameloblastoma in the lungs that developed 12 years after surgery for the primary lesion. As is typical for metastatic ameloblastomas, the tumor was incidentally found on radiography and surgically removed. However, the tumor exhibited accelerated progression with pleural metastasis after surgical removal, which is unusual in metastatic

APA, Harvard, Vancouver, ISO, and other styles

44

Park, Jin Suk, Yasemin Kaygusuz, Carson Kenum, et al. "Abstract A007: Emergence of metastasis-initiating cells during lung adenocarcinoma progression." Cancer Research 84, no. 22_Supplement (2024): A007. http://dx.doi.org/10.1158/1538-7445.tumbody-a007.

Full text

Abstract:

Abstract Metastatic lung adenocarcinoma (LUAD) is responsible for the most cancer-related deaths worldwide, and only a subset of cells is capable of metastasizing. Our lab has previously shown that these metastasis-initiating cells express the transmembrane glycoprotein called L1CAM and exhibit characteristics of a fetal lung developmental continuum, ranging from early progenitor states to more differentiated states. The exact signal by which progenitor cells with high metastatic potentials are generated remains unknown. Here, we demonstrate that L1CAM facilitates the signaling cascades necess

APA, Harvard, Vancouver, ISO, and other styles

45

Yang, Beng, Xiaode Feng, Hua Liu, et al. "High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma." Oncogene 39, no. 42 (2020): 6529–43. http://dx.doi.org/10.1038/s41388-020-01450-5.

Full text

Abstract:

Abstract Exosomes play an important role in intercellular communication and metastatic progression of hepatocellular carcinoma (HCC). However, cellular communication between heterogeneous HCC cells with different metastatic potentials and the resultant cancer progression are not fully understood in HCC. Here, HCC cells with high-metastatic capacity (97hm and Huhm) were constructed by continually exerting selective pressure on primary HCC cells (MHCC-97H and Huh7). Through performing exosomal miRNA sequencing in HCC cells with different metastatic potentials (MHCC-97H and 97hm), many significan

APA, Harvard, Vancouver, ISO, and other styles

46

Pantina, Vincenzo Davide. "Abstract 5924: Intratumor heterogeneity in thyroid cancer progression." Cancer Research 83, no. 7_Supplement (2023): 5924. http://dx.doi.org/10.1158/1538-7445.am2023-5924.

Full text

Abstract:

Abstract Thyroid cancer (CT) is the most common endocrine organs malignancy and is classified into:well-differentiated carcinomas, characterized by favourable prognosis and sensitive to standardtreatments, and undifferentiated carcinomas (UTC), the most lethal and highly refractoryagainst current therapies. UTCs have invasive and highly metastatic phenotype. The metastaticcascade model described distant metastasis origin deriving from cancer cells that seed to lymphnode and then disseminate to distant organs. According to this, lymphadenectomy was definedas an elective therapy for TC patients.

APA, Harvard, Vancouver, ISO, and other styles

47

Radojkovic, Milan, Jasmina Gligorijevic, Miroslav Stojanovic, Goran Stanojevic, and Ivan Ilic. "Laparotomy site implantation metastasis of carcinoma of the papilla of Vater." Scottish Medical Journal 62, no. 3 (2017): 119–21. http://dx.doi.org/10.1177/0036933017715958.

Full text

Abstract:

Introduction Carcinomas of the papilla of Vater make up a heterogeneous group of tumours arising from different types of epithelium. Regional lymph nodes, liver and lungs are the primary sites of metastatic progression of these tumours. Case presentation We present a patient with an abdominal incision site metastasis of low-grade (mixed type) adenocarcinoma of the papilla of Vater one year after pylorus-preserving pancreaticoduodenectomy. Implantation metastasis of low-grade ampullary carcinoma in the laparotomy wound after open Whipple’s procedure is unusual. Conclusion Adjuvant chemoradiatio

APA, Harvard, Vancouver, ISO, and other styles

48

Oh-Hohenhorst, Su Jung, and Tobias Lange. "Role of Metastasis-Related microRNAs in Prostate Cancer Progression and Treatment." Cancers 13, no. 17 (2021): 4492. http://dx.doi.org/10.3390/cancers13174492.

Full text

Abstract:

Prostate cancer (PCa) is one of the most prevalent cancer types in males and the consequences of its distant metastatic deposits are the leading cause of PCa mortality. Therefore, identifying the causes and molecular mechanisms of hematogenous metastasis formation is of considerable clinical importance for the future development of improved therapeutic approaches. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at the post-transcriptional level by targeting messenger RNAs. Numerous studies have identified miRNAs as promotors or inhibitors of metastasis and revealed,

APA, Harvard, Vancouver, ISO, and other styles

49

Zelefsky, Michael J., James A. Eastham, Angel M. Cronin, et al. "Metastasis After Radical Prostatectomy or External Beam Radiotherapy for Patients With Clinically Localized Prostate Cancer: A Comparison of Clinical Cohorts Adjusted for Case Mix." Journal of Clinical Oncology 28, no. 9 (2010): 1508–13. http://dx.doi.org/10.1200/jco.2009.22.2265.

Full text

Abstract:

Purpose We assessed the effect of radical prostatectomy (RP) and external beam radiotherapy (EBRT) on distant metastases (DM) rates in patients with localized prostate cancer treated with RP or EBRT at a single specialized cancer center. Patients and Methods Patients with clinical stages T1c-T3b prostate cancer were treated with intensity-modulated EBRT (≥ 81 Gy) or RP. Both cohorts included patients treated with salvage radiotherapy or androgen-deprivation therapy for biochemical failure. Salvage therapy for patients with RP was delivered a median of 13 months after biochemical failure compar

APA, Harvard, Vancouver, ISO, and other styles

50

Izraely, Sivan, Shlomit Ben-Menachem, Sapir Malka, et al. "The Vicious Cycle of Melanoma-Microglia Crosstalk: Inter-Melanoma Variations in the Brain-Metastasis-Promoting IL-6/JAK/STAT3 Signaling Pathway." Cells 12, no. 11 (2023): 1513. http://dx.doi.org/10.3390/cells12111513.

Full text

Abstract:

Previous studies from our lab demonstrated that the crosstalk between brain-metastasizing melanoma cells and microglia, the macrophage-like cells of the central nervous system, fuels progression to metastasis. In the present study, an in-depth investigation of melanoma-microglia interactions elucidated a pro-metastatic molecular mechanism that drives a vicious melanoma-brain-metastasis cycle. We employed RNA-Sequencing, HTG miRNA whole transcriptome assay, and reverse phase protein arrays (RPPA) to analyze the impact of melanoma-microglia interactions on sustainability and progression of four

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!